2024
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry
Maurizi N, Antiochos P, Owens A, Lakdwala N, Saberi S, Russell M, Fumagalli C, Skalidis I, Lin K, Nathan A, De Feria Alsina A, Reza N, Stendahl J, Abrams D, Semsarian C, Clagget B, Lampert R, Wheeler M, Parikh V, Ashley E, Michels M, Rossano J, Ryan T, Ingles J, Ware J, Ho C, Helms A, Day S, Olivotto I. Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry. Circulation 2024, 150: 1377-1390. PMID: 39355918, PMCID: PMC11493522, DOI: 10.1161/circulationaha.124.069378.Peer-Reviewed Original ResearchSeptal reduction therapyHCM-related deathOutflow tract obstructionObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyHeart failureComposite outcomeMaximal left ventricular outflow tract gradientRecurrent left ventricular outflow tract obstructionRelief of outflow tract obstructionLeft ventricular outflow tract gradientLeft ventricular outflow tract obstructionReduction therapyVentricular outflow tract obstructionDe novo atrial fibrillationPredictor of adverse outcomesOccurrence of heart failureAlcohol septal ablationOutflow tract gradientEvent-free survivalLong-term disease courseHypertrophic cardiomyopathy centersLong-term reliefCox proportional hazards modelsLong-term outcomes
2022
Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 1: Technical Considerations and Perfusion and Neuronal Imaging.
Stendahl JC, Kwan JM, Pucar D, Sadeghi MM. Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 1: Technical Considerations and Perfusion and Neuronal Imaging. Journal Of Nuclear Medicine 2022, 63: 649-658. PMID: 35487563, DOI: 10.2967/jnumed.121.263506.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsUnmet diagnostic needsCardiovascular medicineNeuronal imagingImaging of inflammationHeart failureValvular diseaseTechnical considerationsDiagnostic needsCardiac amyloidosisUnmet ClinicalNew radiotracersCardiovascular imagingPersonalized therapyPerfusion tracerPET perfusion tracerThrombosisRadiotracer developmentRadiotracerPerfusionF-FlurpiridazImagingReviewMedicineKey technical considerationsMolecular characterization